Afamelanotide in fair-skinned Parkinson’s patients
June 17, 2024 20:39 ET | Clinuvel Pharmaceuticals Limited
CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
March 28, 2024 04:25 ET | Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
March 04, 2024 21:38 ET | Clinuvel Pharmaceuticals Limited
CLINUVEL joined an intimate evening at Lady Gaga and Michael Polansky's Malibu home to celebrate the future of photomedicine
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
February 28, 2023 18:58 ET | Clinuvel Pharmaceuticals Limited
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level...
CLINUVEL Financial Performance
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
February 23, 2023 18:14 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE®...
Full Latin without Latin logo.png
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
February 01, 2023 19:14 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV)...
Full Latin without Latin logo.png
CLINUVEL Trial Results Show Drug Reduces DNA Damage
January 15, 2023 18:23 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of...
Vitiligo repigmentation in CUV102 study
CLINUVEL progresses vitiligo treatment program
May 09, 2022 21:33 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide...
CUV801 MRI-FLAIR results
Positive final results in stroke
May 03, 2022 20:24 ET | Clinuvel Pharmaceuticals Limited
 ASX: XETRA-DAX:  Level 1 ADR:CUV UR9 CLVLY  EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
Full Latin without Latin logo.png
Letter to shareholders from CLINUVEL’s CEO
April 29, 2022 01:20 ET | Clinuvel Pharmaceuticals Limited
LONDON, April 29, 2022 (GLOBE NEWSWIRE) --       Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...